Tarveda to Present at the BIO CEO & Investor Conference February 14
WATERTOWN, MA — February 9, 2017 — Tarveda Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference. Mr. Fromkin will discuss the Company’s Pentarin miniaturized drug conjugate platform, including PEN-221, which is currently in clinical evaluation for the treatment of patients with neuroendocrine and small cell lung cancers. The presentation will take place on Tuesday, February 14, 2017 at 11:00 a.m. Eastern Time in New York, NY.
Tarveda is developing Pentarins, potent and selective miniaturized drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cell killing agent through an optimized chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for effective penetration and distribution into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics
Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new class of potent and selective miniaturized drug conjugates with enhanced targeting capabilities for the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug candidate, PEN 221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine and small cell lung cancers. PEN-221 comprises a highly selective peptide that targets SSTR2 linked to the potent cytotoxic DM1 through a cleavable linker. Tarveda is also advancing its HSP90 drug conjugate platform with lead drug candidate PEN 866, which is a miniaturized HSP90 targeting drug conjugate that comprises a small molecule HSP90 targeting ligand conjugated to SN 38, the highly potent, active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of its pharmaceutical collaborators.www.tarveda.com
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060